MARKET

CLVS

CLVS

Clovis Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.24
-0.34
-6.09%
After Hours: 5.26 +0.02 +0.38% 19:55 10/26 EDT
OPEN
5.49
PREV CLOSE
5.58
HIGH
5.51
LOW
5.20
VOLUME
3.30M
TURNOVER
--
52 WEEK HIGH
17.37
52 WEEK LOW
2.930
MARKET CAP
462.18M
P/E (TTM)
-0.8637
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Are Dipping Their Toes Back Into Clovis Oncology Inc (CLVS)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 10/15 03:15
Most Heavily Shorted Stocks: October 2020
This article presents a list of stocks with the highest short interest as a percentage of shares outstanding.An unprecedented year amid the COVID-19 pandemic driving historic volatility has represented significant trading opportunities for short-sellers.We analyze key trends and how to best interpret the short interest data.
Seekingalpha · 10/14 17:38
How Much Is Clovis Oncology, Inc. (NASDAQ:CLVS) Paying Its CEO?
This article will reflect on the compensation paid to Patrick Mahaffy who has served as CEO of Clovis Oncology, Inc...
Simply Wall St. · 10/13 11:47
The Top Mid-Cap Stocks To Target On Down Days
The best-rated mid-cap sector is consumer goods.The top scoring industry is specialty retail.Churchill Downs, Simply Good Foods, and Wolverine World Wide are among the best scoring stocks this week.
Seekingalpha · 10/03 11:04
Clovis Oncology (CLVS) Investor Presentation - Slideshow
The following slide deck was published by Clovis Oncology, Inc. in conjunction with this event.
Seekingalpha · 09/22 21:36
Cassava Sciences, Evogene leads the healthcare gainers' pack, Ayala Pharmaceuticals, Clovis Oncology amond major losers
Gainers: Cassava Sciences (SAVA) +41%, Evogene (EVGN) +26%, AlloVir (ALVR) +15%, Abeona Therapeutics (ABEO) +15%, Sonoma Pharmaceuticals (SNOA) +14%.Losers: Ayala Pharmaceuticals (AYLA) -12%, Clovis Oncology (CLVS) -10%, Checkpoint Therapeutics (CKPT) -9%, Seres Therapeutics (MCRB) -8%, Innate Pharma (IPHA) -5%.
Seekingalpha · 09/18 14:56
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
Business Wire · 09/17 07:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLVS. Analyze the recent business situations of Clovis Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLVS stock price target is 9.00 with a high estimate of 23.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 275
Institutional Holdings: 53.43M
% Owned: 60.57%
Shares Outstanding: 88.20M
TypeInstitutionsShares
Increased
60
13.19M
New
65
2.84M
Decreased
36
3.45M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Independent Director
Ginger Graham
President/Chief Executive Officer/Co-Founder/Director
Patrick Mahaffy
Co-Founder/Executive Vice President
Gillian Ivers-Read
Chief Financial Officer/Executive Vice President
Daniel Muehl
Executive Vice President/General Counsel
Paul Gross
Senior Vice President
C. Dale Hooks
Executive Vice President/Director of Human Resources
Ann Bozeman
Executive Vice President
Lindsey Rolfe
Independent Director
Brian Atwood
Independent Director
Robert Azelby
Independent Director
James Blair
Independent Director
Richard Fair
Independent Director
Keith Flaherty
Independent Director
Paul Klingenstein
Independent Director
Edward McKinley
Independent Director
Thorlef Spickschen
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CLVS
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Clovis Oncology Inc stock information, including NASDAQ:CLVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLVS stock methods without spending real money on the virtual paper trading platform.